ITGA2B and systemic lupus erythematosus: There were significantly more circulating anti-GPIIb/IIIa antibody-producing B cells in patients with primary ITP, SLE, liver cirrhosis, and post-HSCT than in healthy controls (5.4±4.7, 6.0±6.4, 10.0±5.8, and 6.3±8.3 versus 0.3±0.4; P<0.05 for all comparisons).